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DIFFERENTIAL SENSITIVITY 
OF THORACIC MALIGNANT 
TUMORS TO ADENOVIRUS- 
MEDIATED DRUG 
SENSITIZATION GENE 
THERAPY 
Malignant mesothelioma may prove to be an attractive candidate for somatic gene 
therapy with replication-deficient recombinant adenovirus transfer of a toxic, or 
drug sensitization gene. Transfer of the herpes implex thymidine kinase type I gene 
(HSVtk), followed by exposure to the acyclic nucleoside drug ganciclovir, has been 
shown to be an etfective tumor cell killing system. To study generalized applicability, 
we tested a number of thoracic malignant cell lines for their sensitivity to gancyclovir 
after infection with an adenoviral vector containing the HSVtk gene (Ad.RSVtk). 
Using the concentration of gancyclovir required to kill 50% of the cells (IC50) as a 
measure of sensitivity, we detected variable sensitivity among cell lines, with 
mesothelioma most sensitive (IC50 = 0.075 to 2.8 pmol/L gancyclovir), and 
nonlsmall-cell carcinoma lines having an intermediate s nsitivity (IC50 = 1.5 to 100 
/xmol/L). In contrast, an ovarian carcinoma line was extremely resistant (IC50 > 
2000/xmol/L). To study the possible mechanisms for these ditferences, we studied 
cell lines with regard to their abUity to be infected with an adenoviral vector 
containing a marker gene (Ad.CMV/acZ) and expression of the vitronectin receptor 
o~ (an integrin cell adhesion molecule shown to be required for adenovirus 
internalization after initial binding). We found that the degree of lacZ transduction 
correlated with HSVtk sensitivity, whereas vitronectin receptor expression did not, 
suggesting that ditferences in initial viral binding ability, rather than internaliza. 
tion, may explain the sensitivity diferences een in vitro. (J THORAC CARDIOVASC 
SURG 1995;109:626-31) 
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M alignant pleural mesothelioma continues to be 
a elinically frustrating problem because of poor 
response to conventional medical and surgical ther- 
apies. Reported median survival is only 10 to 18 
months and early local tumor recurrence is the 
rule. 1'2 In addition to the fact that no effective 
conventional therapy for mesothelioma has been 
developed, the lack of a significant metastatic com- 
ponent and growth in the potential space of the 
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thoracic cavity make it an attractive candidate for 
somatic gene therapy. We have recently shown that 
recombinant replication-deficient adenovirus may 
be used to transfer novel genetic material to human 
mesothelioma both in vitro and in an in vivo xe- 
nograft tumor model 3 and that human mesotheli- 
oma cetls are killed in vitro when the type I herpes 
simplex thymidine kinase (HSVtk) gene is trans- 
ferred via adenovirus followed by ganciclovir (GCV) 
exposure. 4 GCV is transformed by the viral thymi- 
dine kinase to GCV-tr iphosphate--a purine analog 
competing with normal cell nucleotides for deoxyri- 
bonucleic acid incorporation during replication and 
other processes. 5 Surprisingly, uninfected tumor 
cells may be killed when infected cells expressing the 
HSVtk gene are treated with GCV (bystander ef- 
fect). This phenomenon is thought o involve trans- 
fer of GCV-triphosphate from infected to unin- 
fected cells via gap junctions or apoptotic vesicles. 6'7 
One issue raised by these studies is the applica- 
bility of this approach to other cell types. For 
successful adenovirus-mediated gene transfer to oc- 
cur, a number of steps must take place (Fig. 1), 
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Fig. 1. Recombinant replication-deficient adenovirus gene transfer. The basic sequence of steps involved 
in adenovirus gene transfer leading to novel protein production in human tumor cells is schematically 
diagrammed. DNA, Deoxyribonucleic a id. 
including initial viral binding (to an, as yet, uniden- 
tified cell surface receptor), internalization (a step 
dependent on the integrins av/33 or av/3»), stepwise 
disassembly of viral proteins within endosomes, and 
transport of the recombinant genetic material to the 
nucleus where it may be transcribed and translated by 
the enzymatic machinery of the cell. 8'9 Because 
differences in many of these mechanisms could be 
operative in various cell types, we tested the ability 
of Ad.RSVtk/GCV to induce cell killing in a number 
of mesothel ioma and non-small-cell carcinoma lines 
and correlated sensitivity to GCV with the ability to 
express an adenovirus-transmitted marker gene and 
with vitronection receptor expression. 
Materials and methods 
Cell lines. Isolation and maintenance of the human 
mesothelioma lines REN, HeMe-B, 1-45, and non-small- 
cell carcinoma A549 are described elsewhere. 3 The HPM 
normal human mesothelial cell line was the gift of Dr. C. 
Broaddas (University of California at San Francisco). 
Human non-small-cell carcinoma lines H460 and H1264 
were the gift of Dr. C. Allegra (National Cancer Institute), 
and SK-MES-1, Calu-6 were obtained from ATCC (Rock- 
ville, Md). Ovcar-5 (human ovarian carcinoma) was the 
gift of Dr. T. Hamilton (Fox Chase Cancer Institute), and 
II-45 (rat mesothelioma) was furnished by Dr. C. Walker 
(M.D. Anderson Cancer Center). Cells were passaged in 
RPMI (Mediatech, Washington, D.C.) with 10% fetal 
bovine serum (RPMI-10). 
Reeombinant adenovirus, The production of our adeno- 
virus type 5 mutant replication-deficient vectors by homolo- 
gous recombination techniques has been described in detail 
elsewhere.lO, a~ The Ad.CMVlacZ and Ad.RSVtk constructs 
were the gift of Dr. J. M. Wilson (University of Pennsylvania 
Institute for Human Gene Therapy). 
Cell culture infection with Ad.CMV/acZ and Ad.RSVtk. 
One hundred microliters of Ad.CMVlacZ (100 viral par- 
ticles per tumor cell) was placed on confluent 2.5 cm 2 per 
well culture plates. Plates were incubated at 37 ° C for 3 
hours, and then virus was removed. For Ad.RSVtk exper- 
iments, confluent cultures of all lines in 25 cm 2 flasks were 
infected with virus at a ratio of 100 partieles per cell. One 
milliliter of viral solution was placed on the cells, which 
were then incubated at 37 ° C for 3 hours, after which time 
virus was removed. 
X-gal staining for 18-galaetosidase (lacZ gene transfer). 
Two days after infection with Ad.CMVIacZ, cells were 
stained with the/3-galactosidase (/3-gal) substrate, X-gal. 
This staining method has been described in detail else- 
where. ~2 Expression of the gene for/3-gal was indicated by 
discrete cells staining an intense blue color. 
In vitro ganeielovir sensitivity assay. Viable cell num- 
ber was assessed by means of a colorimetric assay (MTI" 
cell proliferation assay, Promega Corporation, Madison, 
Wis.). Confluent 25 cm 2 culture flasks were exposed to 
Ad.RSVtk for 3 hours (100 particles per cell). Twenty-four 
hours later, Ad.RSVtk-infected and uninfected cells were 
plated at 6000 cells per well in 96-well culture plates. After 
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Table I. Comparison of in vitro sensitivity of a 
number of human thoracic tumor and other cell 
lines to the adenovirus vector-mediated HSVtk/GCV 
system, efficiency of transduction with an adenovirus 
transferring a marker gene (Ad. CMVlacZ), and 
percentage of cells expressing the oB integrin by 
fluorescence activated cell sorting 
Cell line IC50 lacZ + o~ + 
1-45 a 0.075 90% 53.7% 
Calu-6 b 1.0 80% 98.6% 
SK-Mes-1 b 1.2 60% 34.6% 
REN a 1.5 60% 46.7% 
HeMe B a 2.8 20% N/A 
H460 b 10 30% 65.5% 
HPM 25 5% 8.4% 
A549 b 75 5% 98.4% 
H1264 b 100 30% 30.1% 
II-45 (rat) 60 30% N/A 
Ovcar5 >2000 <1% 53.7% 
1C50, Concentration of GCV required to kill 50% of ceUs as compared 
with uninfected control cells of the same line; lacZ, the Escherichia coli 
/3-galactosidase gene; %, cell surface integrin; cell lineß human malignant 
mesothelioma; cell lines b, human on-small-cell carcinoma; HPM, human 
normal mesothelial line; Ovcar5, human ovarian carcinoma; 11-45, Fisher 
rat malignant mesothelioma; N/A, not evaluated. 
24 hours, medium was replaced with RPMI-10 containing 
0 to 2000 tzmol/L GCV, 9-[1,3 dihydroxy-2-propoxy- 
methyl]-guanine (Syntex Laboratories, Palo Alto, Calif.). 
Five days later, cells were assayed with the MTT assay. 
Fluorescence activated eell sorting for o~ v integrin. 
Cells were incubated with a negative control mõnoclonal 
antibody or 10 mg/ml of monoclonal human av integrin 
antibody (gift of Dr. David Cheresh 13) for 1 hour, and 
then incubated for 30 minutes with fluorescein isothiocya- 
nate-conjugated F(ab') 2 goat antimouse immunoglobulin 
G. Cells from each tumor line were analyzed for fluores- 
cence intensity by flow cytometry with a Cytofluorograph 
50H sorter equipped with 2150 Data Handling (Ortho 
Instruments, Westwood, Mass.). 
Resuits 
Human mesothelioma nd non-small-eell earei- 
noma eell lines exhibit differential in vitro sensitiv- 
ity to the Ad.RSVtk/GCV therapentie system. To 
determine the etticacy of the Ad.RSVtk/GCV sys- 
tem on different human thoracic malignant cell 
types, the in vitro sensitivity to GCV exposure after 
adenovirus transfer of HSVtk was evaluated in three 
mesotheliomas, five non-small-cell carcinomas, and 
one line each derived from normal thoracic me- 
sothelium and ovarian carcinoma. We also evalu- 
ated one rat malignant mesothelioma cell line. 
Marked differences in GCV dose required for elim- 
ination of 50% of cells as compared with untreated 
control cells (IC50) was noted (Table I). All me- 
sothelioma lines exhibited an IC50 GCV dose of less 
than 3 /zm (range 0.0075 to 2.8 tzmol/L), whereas 
the IC50 of the non-small-cell carcinoma cell lines 
was generally higher, varying from 1.0 to 100/zmol/L 
GCV. HPM, the cell line derived from normal 
human mesothelium, required a GCV dose approx- 
imately tenfold greater than the least sensitive me- 
sothelioma line and Ovcar-5, a human ovarian car- 
cinoma cell line, was extremely insensitive to the 
effects of GCV(IC50 > 2000/zmol/L). 
Expression of the fibronectin-binding reeeptor «, 
does not correlate with HSVtk/GCV sensitivity. A1- 
though the exact nature of the adenoviral cell 
surface receptor has not been elucidated, it has 
recently been shown that interaction with a sec- 
ond set of receptors, the integrins Otv~ 3 or  av/3 5, is 
necessary for internalization of virus, s We there- 
fore determined the density of surface a v integrin 
by fluorescence activated cell sorting analysis to 
see whether the differential ability to express 
adenovirus-derived proteins might be due to a 
lack of surface protein needed to internalize 
adenovirus. As illustrated in Table I and Fig. 2, 
the amount of a v expressed by the tumor cells was 
variable and did not correlate with sensitivity to 
HSVtk/GCV or to lacZ expression. 
Ad.CMV/acZ transduction efficiency correlates 
with Ad.RSVtk/GCV sensitivity. The resistance of 
some cell lines to Ad.RSVtk/GCV could be due to 
many factors including decreased etficiency of vital 
entry, transcription of transgene, or activity of HSVtk, 
as weh as an inherent resistance to the effects of 
phosphorylated GCV products (see Fig. 1). To begin 
to dissect hese mechanisms, we infected the cells with 
a second adenovirus vector containing the lacZ marker 
gene under the control of the cytomegalovirus pro- 
moter. Failure to express this independent gene would 
suggest problems with viral entry or intemalization 
rather than resistance to the effects of GCV. As is 
noted in Table I and Fig. 3, the percentage of 
Ad.CMVlacZ transduced cells related directly with 
HSVtk/GCV sensitivity in that it was inversely corre- 
lated with the IC50 GCV dose required after Ad.RS- 
Vtk infection. The slopes of simple lines fitted to the 
curves plotting IC50 and percentage of/3-gal express- 
ing cells were similar (13.7 and -12.8, respectively). 
Mesothelioma cell lines tended to show a higher 
relative percentage of lacZ positive cells. 
Diseussion 
The human mesothelioma cell lines evaluated inthis 
study appeared to be more sensitive to the HSVtk/ 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 109, Number 4 
Smythe et al. 629 
IC50 
(mcM GCV) 
110- 
90- 
70 
50 
3O 
10 
-10 
~J ~J 
"~ I ~. ~cs0 I ,",_ 
• 1""0""  av I ; I  == , • I i i t  r 
• t • " |  t /  
• t m 111 
I • I i l "  » 11 j / I  
: I ~ : r "  
u ~ " • .q I 4'  111 • II • o--'~ • f I 
• |  
I I I I 1 I I I 
1 2 3 4 5 6 7 8 
Cell Lines 
100 
80 
' 60  % alpha v 
positive 
,40 cells 
20 
Fig. 2. Comparison of human cell line sensitivity to adenovirus vector-mediated HSVtk system and o~ 
integrin expression. No obvious relationship exists. CeIl line 1, 1-45; line 2, Calu-6; Iine 3, SK-MES-1; line 
4, REN; line 5, H460; line 6, HPM; line 7, A549; line 8, H1264. 
IC50 
(mcM GCV) 
o. I = =c5ol 
",«_ I---o-- lacz I ,=  
,o \ / 
70 b - - -o  / 
', / 
50 \ 
30 "b, / ,o 
Y / 
110" 
"100 
80 
"60 
'40 
lOlo 1 ,2o 
o- - -O  
- -  i i I I i i i i 
1 2 3 4 5 6 7 8 
% lacZ 
positive 
cells 
Cell Lines 
Fig. 3. Comparison ofhuman cell line sensitivity oadenovirus vector-mediated HSVtk system and Ad.CMV/acZ 
transducüon efficiency. The magnitude ofsimple lines fit to these curves i  similar. (See cell line legend to Fig. 2.) 
GCV gene therapy system than both non-small-cell 
carcinoma nd normal cell fines tested. The concen- 
tration of GCV required to reach IC50 for these 
mesothelioma cell lines is weil below what is routinely 
achieved in patients (-20/zmol/L) treated for herpes- 
virus infections at approved clinical doses. 14 Although 
the relationship between the sensitivities of cells to 
GCV in vitro and in vivo remains to be determined, we 
have shown that xenograft models of human solid 
tumor mesothelioma are extremely sensitive to this 
treatment method in immunocompromised mice, is 
thus suggesting that the HSVtk /GCV system may have 
wider applicability. 
As with any new therapy, it is important to analyze 
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sensitivity of potential target diseases o that rational 
decisions may be made regarding indications for use. 
The data presented here suggest hat ditterences in 
sensitivity to HSVtk/GCV may be due to cellular 
resistance to adenoviral binding and/or uptake rather 
than inherent resistance to the effect of the HSVtk 
enzyme. This conclusion is based on the observafion 
that resistance to GCV is correlated with expression of 
another adenoviral vector containing a marker gene, 
Ad.CMV/acZ. Although more work will be required 
to determine which step in the vital c2¢cle (see Fig. 1) is 
blocked in resistant cells, our study does suggest hat 
the problem is not due simply to lack of expression of 
vitronectin receptor by resistant cell lines. Evaluation 
of initial viral binding to adenoviral cell sufface recep- 
tors, using radiolabeled virus, 9 may be useful in resolv- 
ing this issue further. 
In summary, this study has shown that sensitivity to 
the HSVtk/GCV can vary over a wide range. Mesothe- 
lioma and non-small-cell ung cancer cell lines are 
quite sensitive, whereas at least one ovarian carcinoma 
line was extremely resistant. The mechanism for this 
resistance isunknown but appears to be due to factors 
related to viral uptake, internalization, or expression 
rather than resistance to the HSVtk enzyme. An 
understanding of the relative sensitivities of various 
neoplasms to this gene therapy technique and the 
mechanisms responsible for this sensitivity will lead to 
rational and targeted clinical application. 
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Discussion 
Dr. Martin F. MeKneally (Toronto, Ontario, Canada). 
Can you teil us anything about your hopes in terms of 
application i the human model? Will it be limited only to 
the tumor cell, or if there is spillover to the normal cells, 
will it be destructive or harmful? 
Dr. Smythe. We and others have shown that when 
recombinant adenovirus i placed into a body cavity lined 
with mesothelium the normal mesothelium is infected 
along with any tumor that may be growing in that cavity; 
however, it seems to form a barrier to penetration of the 
virus into normal tissues. It does not easily traverse the 
normal mesothelium. 
In addition, it appears that normal cells that are not 
rapidly dividing and are not rapidly synthesizing deoxyri- 
bonucleic acid (DNA) and transcribing as much DNA as 
tumor cells are not affected to the same degree. 
We picked mesothelioma asa model system because we 
thought it was an ideal tumor, basically because most 
morbidity is from local disease, and its anatomic distribu- 
tion may allow us to treat without as much concern about 
generalized toxicity. 
I would like to add that we have actually treated 
intraperitoneal preexisting human tumor in our immune- 
deficient mouse model. In contrast to the work I described 
here, in which ceUs are infected in vitro, in these experi- 
ments we infected tumor after it had already been estab- 
lished in the peritoneal cavity, much as you would see in 
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the clinical situation. We found that in 90% of our animals 
we completely eliminated macroscopic disease, and we 
also found that in 80% of animals we completely eradi- 
cated microscopic disease as weil. We are currently work- 
ing on in vivo preclinical toxicity studies with hopes of 
submitting this protocol to the DNA Recombinant Advi- 
sory Committee this fall for consideration of a possible 
clinical trial. 
Dr. Pedro J. del Nido (Pittsburgh, Pa.). You are using 
adenovirus, which sometimes can have variable xpression, 
as a vector. Have you considered just the adeno-associated 
viruses, with which some people have had bettet expression? 
Dr. Smythe. No, actually the adenovirus to date, in a 
number of studies comparing head to head all methods of 
gene transfer, is by far the most effective and etficient 
method, rauch more effective than retrovirus or conven- 
tional methods. 
The adeno-associated virus is a different virus. It is a 
virus that requires co-infection with adenovirus to engen- 
der gene transfer. There are significant technical problems 
right now with production of sutficient amounts of adeno- 
associated virus, and it appears to be a relatively ineificient 
gene transfer vector. 
Dr. Donald L. Morton (Santa Monica, Calif.). How long 
will this transfer gene persist in vitro or in vivo? Do the ceUs 
eliminate the transfer gene or do they continue to express it
for a long period? 
Dr. Smythe. Adenoviral gene transfer is transient com- 
pared with some other methods. A trade-off is efficiency of 
gene transfer. In the case of correction of genetic diseases 
such as cystic fibrosis and familial hypocholesterolemia, it 
would be important o have prolonged expression of a 
gene. For transfer of a toxic or suicide gene, as in this 
study, we believe that durable xpression isnot warranted. 
Our goal is quick eradication of the tumor. 
In addition, there does seem to be an immune response to 
adenovirus. Most of us have seen adenovirus at some point 
in our lives. However, in some studies this has been shown to 
be benefieial in treatment of malignancy. The immune 
response is actually additive to the toxic effect of the gene. 
Dr. Morton. If the gene does not persist, you theoreti- 
cally would have the same problem that you have with 
chemotherapy: resistance. The cells that develop resis- 
tance will be the ones that regrow. 
Dr. Smythe. I do not know that resistance to these sorts 
of therapies has ever been shown in vitro, at least for the 
transfer of toxic or suicide genes. The genes do persist for 
at least 3 weeks even in immune competent animals, 
which would allow a fairly prolonged treatment ime, 
equivalent to what many chemotherapy regimens are. 
